American Association for Cancer Research
13
4
5
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.4%
2 terminated/withdrawn out of 13 trials
71.4%
-15.1% vs industry average
8%
1 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
Role: collaborator
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Role: collaborator
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
Role: lead
The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
Role: collaborator
Digitally Enhanced Smoking Cessation for High Risk Smokers
Role: collaborator
The Cancer of the Pancreas Screening-5 CAPS5)Study
Role: collaborator
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Role: collaborator
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Role: collaborator
Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
Role: collaborator
Radiologically Guided Biopsies of mCRPC
Role: collaborator
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Role: collaborator
Q-Trial in Patients With Hepatitis C
Role: collaborator
A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer
Role: collaborator
All 13 trials loaded